Join us on October 17-20, 2018 for the 18th annual Lymphoma & Myeloma Congress. This program features four days of comprehensive learning as we analyze emerging data, discover innovative treatment methods, and get a glimpse into the future of lymphoma, myeloma, and leukemia disorders.

Target Audience
This educational activity is designed for domestic and international healthcare clinicians, including hematologists and hematologic oncologists, medical, radiation, and surgical oncologists, and other healthcare professionals (physicians, physicians-in-training, oncology nurses, nurse practitioners, pharmacists, physician assistants, etc.) who are involved and/or interested in the treatment of patients with hematologic malignancies.

Learning Objectives
Upon successful completion of these educational activities, participants should be better able to:

Analyze results from genetic testing that may be used to incorporate precision medicine strategies into diagnostic, prognostic, and therapeutic algorithms for patients with hematologic malignanciesDefine mechanisms of action of current and emerging agents for hematologic malignanciesAssess recent and ongoing clinical trial data for existing and novel therapeutics for hematologic malignanciesFormulate evidence-based management strategies for sub-populations with hematologic malignancies (eg, older patients, who is with poor functional capacity)Identify an appropriate sequence of optimal agents for patients with refractory or relapsed hematological malignanciesEvaluate approaches that can be used to improve practice as an interdisciplinary healthcare team to provide better care to patients with hematologic malignanciesCongress Chair
Morton Coleman, MD

Co-Chair, Lymphoma Session
John P. Leonard, MD

Co-Chair, Myeloma Session
Ruben Niesvizky, MD

Co-Chair, CLL Session
Richard R. Furman, MD

Co-Chair, Acute Leukemia and Hematologic Malignancies Session
Gail J. Roboz, MD

Please visit lymphomamyeloma.com for full agenda and accreditation details